Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
Nigel J. Temperton* , Paul K. Chan†, Graham Simmons‡, Maria C. Zambon§, Richard S. Tedder*, Yasuhiro Takeuchi*, and Robin A. Weiss*
Author affiliations: *University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People’s Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; §Health Protection Agency Central Public Health Laboratory, London, United Kingdom
Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction assay with titers measured with pseudotype assay. LV, neutralizing antibody titer by using replication-competent severe acute respiratory syndrome–associated coronavirus (SARS-CoV) (live virus); PV, neutralizing antibody titer by using pseudotype virus; PV90 (filled black diamonds), 90% neutralizing antibody titer by using murine leukemia virus (MLV) (SARS) pseudotype virus; PV50 (open squares), 50% neutralizing antibody titer. Logarithmic trendlines were fitted to the data by using Microsoft Excel 2003 (Microsoft Corp., Redmond, WA, USA). Correlation coefficients for LV versus PV90 and LV versus PV50 are 0.69 and 0.78, respectively.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.